Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA Combined With VAC in Intermediate-to-high-risk Rhabdomyosarcoma
NCT07355855Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tretinoin in rhabdomyosarcoma (RMS) (2 arms), sponsored by Fudan University. Primary endpoint: Event-Free Survival at 2 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tretinoin
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT07355855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355855.